Advances in the development of anti-cancer vaccines

03/2018

MUDr. Zuzana Střížová; MUDr. Michal Podrazil, Ph.D.; prof. MUDr. Jiřina Bartůňková, DrSc.

Ústav imunologie 2. LF UK a FN v Motole, Praha

SUMMARY

Immunotherapy has accomplished an impressive success within the past several years and therefore is widely accepted as a breakthrough therapy in the field of oncology. The rapid development of modern methods has led to generation of highly personalized biological and cellular therapy. In the solid tumor treatment, checkpoint inhibitors turned to be a very perspective therapeutic modality however, the prevention of undesired autoimmune events should be targeted in ongoing clinical trials. In hematological malignancies, application of CAR T cells showed significant results and combining CAR T cells with oncolytic viruses might be a promising approach in the future. Here we provide the systematic review of the modern immune-oncologic approaches and present the course of basic research in the field of cancer immunotherapy.

KEY WORDS

immunotherapy, anti-cancer vaccines